Chris Richard
Direktor/Vorstandsmitglied bei LEAP THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Profil
Christian M.
Richard is currently a Director at Amphivena Therapeutics, Inc., a Director at Rainier Therapeutics, Inc., an Independent Director at Leap Therapeutics, Inc., and the Head of Public Research at Samsara Biocapital LLC.
Prior to his current positions, he was the Senior Vice President of Research at Tekla Capital Management LLC from 2015 to 2020, the Partner & Head of Research at Merlin Nexus from 2004 to 2015, and an Associate Research Scientist at Schering-Plough Research Institute from 1997 to 2001.
Richard holds a graduate degree and an MBA from New York University, and an undergraduate degree from Purchase College, which he received in 1993.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LEAP THERAPEUTICS, INC.
-.--% | 29.01.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Chris Richard
| Unternehmen | Position | Beginn |
|---|---|---|
| LEAP THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 17.01.2023 |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Direktor/Vorstandsmitglied | - |
Amphivena Therapeutics, Inc.
 Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Direktor/Vorstandsmitglied | - |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 01.12.2020 |
Ehemalige bekannte Positionen von Chris Richard
| Unternehmen | Position | Ende |
|---|---|---|
Tekla Capital Management LLC
 Tekla Capital Management LLC Investment ManagersFinance Tekla Capital Management LLC is an independent, SEC-registered investment advisor headquartered in Boston, Massachusetts. Formerly known as Hambrecht & Quist Capital Management LLC, the firm serves as an investment adviser for four closed-end funds – Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. | Analyst-Equity | 01.11.2020 |
Merlin Nexus
 Merlin Nexus Investment ManagersFinance Merlin Nexus is a private equity firm founded in 2001. The firm headquartered in New York. | Private-Equity-Analyst | 28.02.2015 |
Schering-Plough Research Institute
 Schering-Plough Research Institute Medical SpecialtiesHealth Technology Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | 31.12.2001 |
Ausbildung von Chris Richard
| New York University | Graduate Degree |
| Purchase College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LEAP THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Merlin Nexus
Merlin Nexus Investment ManagersFinance Merlin Nexus is a private equity firm founded in 2001. The firm headquartered in New York. | Finance |
Schering-Plough Research Institute
Schering-Plough Research Institute Medical SpecialtiesHealth Technology Schering-Plough Research Institute provides pharmaceutical research. The company is headquartered in Kenilworth, NJ. | Health Technology |
Tekla Capital Management LLC
Tekla Capital Management LLC Investment ManagersFinance Tekla Capital Management LLC is an independent, SEC-registered investment advisor headquartered in Boston, Massachusetts. Formerly known as Hambrecht & Quist Capital Management LLC, the firm serves as an investment adviser for four closed-end funds – Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. | Finance |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
